[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Psoriasis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 209 pages | ID: G37A6C650B4EN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Psoriasis is a chronic autoimmune disease characterized by abnormal growth of the skin cells. It forms skin patches above the skin and it is not contagious. Psoriasis skin patches are red and itchy. There are different types of psoriasis namely guttate psoriasis, plaque psoriasis, pustular psoriasis, erythrodermic psoriasis and inverse psoriasis. Plaque psoriasis is common and constitutes about 90% of psoriasis cases. The diagnosis of psoriasis is typically made by obtaining information from the physical examination of the skin, medical history, and relevant family health history. Psoriasis affects skin over the elbows, knees, and scalp and is often itchy. Although any area may be involved, it tends to be more common at sites of friction, scratching, or abrasion. Currently, there was no cure for psoriasis. However, treatment is focused on curing the symptoms. Treatment may include steroid creams, vitamin D3 cream, UV light, and immunosuppressants.

Global psoriasis treatment market is driven by increase in smoking and alcohol consumption trends globally. Increased spending on medicines and escalating health care expenditure are the key growth drivers of the market. Psoriasis treatment mainly treated by topical agents only. The Recent launch of systemic products into the market expected to drive the growth of the market. However, high cost of the drugs and side-effects associated with the existing medication for psoriasis are expected to hinder the psoriasis treatment market during the forecast period.

Psoriasis treatment market segmented on the basis of drug class, type, route of administration, and distribution channel

Based on drug class, global psoriasis treatment market is segmented into
  • TNF Inhibitors
  • Vitamin D Analogues
  • Interleukin Blockers
  • Topical Corticosteroids
  • Monoclonal Antibodies
  • Others
Based on type, global psoriasis treatment market is segmented into
  • Plaque Psoriasis
  • Guttate Psoriasis
  • Flexural Psoriasis
  • Inverse Psoriasis
  • Psoriatic Psoriasis
Based on route of administration, global psoriasis treatment market is segmented into
  • Oral
  • Topical
  • Parenteral
Based on distribution channel, psoriasis treatment system is segmented into
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Psoriasis treatment market is expected to show significant growth rate owing to prevalence rates and severity of the disease. According to World Health Organization (WHO), 1.3%-34.7% of psoriasis patients develop chronic psoriatic arthritis, which may lead to joint deformations and disability. World Health Organization (WHO) also predicts that psoriasis affects about 100 million people with prevalence rates of 0.09% to 11.43% in different countries. The most common type of psoriasis is plaque psoriasis, affecting 90% of all psoriasis cases. Market players are focusing on R&D to develop new drugs and treatments for psoriasis. The market has a handful of drugs and dominated by generics and biologics. Market players heavily influencing the treatment decisions. Due to the entry of biosimilars into the market, there is availability of cheaper drugs to treat psoriasis and it leading to increased availability and increase market size. In addition, market has drug pipelines which are expected to boost the psoriasis treatment market during forecast period.

Geographically, psoriasis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts largest market in the psoriasis treatment market due to high prevalence of the disease. According to American Academy of Dermatology, approximately 7.5 Mn people in the United States have psoriasis. In Europe, the psoriasis treatment market is expected to grow at significant rate due to factors such as increased prevalence and growing awareness about skin diseases and recent launch of biosimilars such as elerzi, amzevita. In Asia-Pacific region, India and China are expected to be fastest growing market due to developing infrastructure and rapid growth in awareness and available treatment options for psoriasis.

Some of the market players in psoriasis treatment market include Amgen Inc. (U.S), Eli Lilly and Company(U.S), Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc., (U.S) Pfizer, Inc. (U.S), AstraZeneca (U.K), AbbVie Inc. (U.S), LEO Pharma A/S (Denmark) and Biogen (U.S) to name a few.

In July 2017, Janssen Biotech, Inc.’s tremfya (guselkumab) approved by U.S. Food and Drug Administration (FDA) for the treatment of adults living with moderate to severe plaque psoriasis

In February 2017, US Food and Drug Administration (FDA) approved siliq(brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis. This drug was developed by Valeant Pharmaceuticals by partnering with AstraZeneca

REPORT OUTLINE:
  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY

2. GLOBAL PSORIASIS TREATMENT MARKET INTRODUCTION

2.1. Global Psoriasis Treatment Market– Taxonomy
2.2. Global Psoriasis Treatment Market–Definitions
  2.2.1. Drug Class
  2.2.2. Psoriasis Type

3. GLOBAL PSORIASIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Psoriasis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Psoriasis Treatment Market– Recent Market Introductions

4. GLOBAL PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. TNF Inhibitors
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Vitamin D Analogues
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Interleukin Blockers
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Topical Corticosteroids
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Monoclonal Antibodies
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Others
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY PSORIASIS TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Plaque Psoriasis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Guttate Psoriasis
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Flexural Psoriasis
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Inverse Psoriasis
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Psoriatic Psoriasis
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis

7. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Topical
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Pareneteral
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis

9. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. TNF Inhibitors
    10.1.1.2. Vitamin D Analogues
    10.1.1.3. Interleukin Blockers
    10.1.1.4. Topical Corticosteroids
    10.1.1.5. Monoclonal Antibodies
    10.1.1.6. Others
  10.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Plaque Psoriasis
    10.1.2.2. Guttate Psoriasis
    10.1.2.3. Flexural Psoriasis
    10.1.2.4. Inverse Psoriasis
    10.1.2.5. Psoriatic Psoriasis
  10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Oral
    10.1.3.2. Topical
    10.1.3.3. Parenteral
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospital Pharmacies
    10.1.4.2. Retail Pharmacies
    10.1.4.3. Online Pharmacies
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  10.1.7. North America Psoriasis Treatment Market Dynamics – Trends

11. EUROPE PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. TNF Inhibitors
    11.1.1.2. Vitamin D Analogues
    11.1.1.3. Interleukin Blockers
    11.1.1.4. Topical Corticosteroids
    11.1.1.5. Monoclonal Antibodies
    11.1.1.6. Others
  11.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Plaque Psoriasis
    11.1.2.2. Guttate Psoriasis
    11.1.2.3. Flexural Psoriasis
    11.1.2.4. Inverse Psoriasis
    11.1.2.5. Psoriatic Psoriasis
  11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Oral
    11.1.3.2. Topical
    11.1.3.3. Parenteral
  11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospital Pharmacies
    11.1.4.2. Retail Pharmacies
    11.1.4.3. Online Pharmacies
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  11.1.7. Europe Psoriasis Treatment Market Dynamics – Trends

12. ASIA-PACIFIC PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. TNF Inhibitors
    12.1.1.2. Vitamin D Analogues
    12.1.1.3. Interleukin Blockers
    12.1.1.4. Topical Corticosteroids
    12.1.1.5. Monoclonal Antibodies
    12.1.1.6. Others
  12.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Plaque Psoriasis
    12.1.2.2. Guttate Psoriasis
    12.1.2.3. Flexural Psoriasis
    12.1.2.4. Inverse Psoriasis
    12.1.2.5. Psoriatic Psoriasis
  12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Oral
    12.1.3.2. Topical
    12.1.3.3. Parenteral
  12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospital Pharmacies
    12.1.4.2. Retail Pharmacies
    12.1.4.3. Online Pharmacies
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  12.1.7. Asia-Pacific Psoriasis Treatment Market Dynamics – Trends

13. LATIN AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. TNF Inhibitors
    13.1.1.2. Vitamin D Analogues
    13.1.1.3. Interleukin Blockers
    13.1.1.4. Topical Corticosteroids
    13.1.1.5. Monoclonal Antibodies
    13.1.1.6. Others
  13.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Plaque Psoriasis
    13.1.2.2. Guttate Psoriasis
    13.1.2.3. Flexural Psoriasis
    13.1.2.4. Inverse Psoriasis
    13.1.2.5. Psoriatic Psoriasis
  13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Oral
    13.1.3.2. Topical
    13.1.3.3. Parenteral
  13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospital Pharmacies
    13.1.4.2. Retail Pharmacies
    13.1.4.3. Online Pharmacies
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  13.1.7. Latin America Psoriasis Treatment Market Dynamics – Trends

14. MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.1.1. TNF Inhibitors
    14.1.1.2. Vitamin D Analogues
    14.1.1.3. Interleukin Blockers
    14.1.1.4. Topical Corticosteroids
    14.1.1.5. Monoclonal Antibodies
    14.1.1.6. Others
  14.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Plaque Psoriasis
    14.1.2.2. Guttate Psoriasis
    14.1.2.3. Flexural Psoriasis
    14.1.2.4. Inverse Psoriasis
    14.1.2.5. Psoriatic Psoriasis
  14.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Oral
    14.1.3.2. Topical
    14.1.3.3. Parenteral
  14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Hospital Pharmacies
    14.1.4.2. Retail Pharmacies
    14.1.4.3. Online Pharmacies
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  14.1.7. MEA Psoriasis Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Amgen Inc. (U.S)
  15.2.2. Eli Lilly and Company(U.S)
  15.2.3. Novartis AG (Switzerland)
  15.2.4. Merck & Co., Inc. (U.S)
  15.2.5. Johnson & Johnson Services, Inc., (U.S)
  15.2.6. Pfizer, Inc. (U.S)
  15.2.7. AstraZeneca (U.K)
  15.2.8. AbbVie Inc. (U.S)
  15.2.9. LEO Pharma A/S (Denmark)
  15.2.10. Biogen (U.S)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications